The Medical Letter on Drugs and Therapeutics
Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved elagolix (Orilissa – AbbVie), an oral gonadotropin-releasing hormone (GnRH) antagonist, for management of moderate to severe pain associated with endometriosis.

MECHANISM OF ACTION — Elagolix competitively binds to pituitary GnRH receptors, inhibiting GnRH signaling, reducing pituitary secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), and decreasing ovarian production of estradiol and progesterone.

ENDOMETRIOSIS — Endometriosis is a chronic inflammatory condition that affects up to 10% of reproductive-age women. It is characterized by the presence of endometrial tissue outside the uterus, generally in the pelvic cavity, but distant migration can occur. Clinical features include dysmenorrhea, nonmenstrual pelvic pain, dyspareunia, and infertility. Pain associated with endometriosis adversely affects daily activities and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain
Article code: 1556c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian